Hyperhidrosis Treatment Market Regional Analysis

Global Hyperhidrosis Treatment Market size was valued at USD 671.2 million in 2023 and is poised to grow from USD 707.44 million in 2024 to USD 1077.5 million by 2032, growing at a CAGR of 5.4% during the forecast period (2025-2032).

There are a significant number of participants in the hyperhidrosis treatment market, which is moderately consolidated. Currently, a small subset of the key firms control the majority of the market share. Business organisations are concentrating on organic growth techniques such product launches, product approvals, and others like patents and events. Acquisitions and partnerships & collaborations were two inorganic growth tactics that were observed in the market. The expansion of the companies' operations and clientele of market participants has been made possible by these initiatives. The growing demand for hyperhidrosis treatments in the global market is predicted to provide the market participants in the hyperhidrosis treatment sector with attractive growth prospects in the future. In addition, some major corporations are actively acquiring other businesses to strengthen their market positions globally (Sientra acquired Miramar). 'AbbVie Inc. (US)', 'Avanor Healthcare Ltd. (UK) ', 'Brickell Biotech Inc. (US) ', 'Dermadry Laboratories Inc. (Canada) ', 'Dermavant Sciences Inc. (US) ', 'Hugel, Inc. (South Korea) ', 'Eirion Therapeutics, Inc. (US) ', 'Eli Lilly and Company (US) ', 'Intas Pharmaceuticals Ltd. (India) ', 'Kaken Pharmaceutical Co., Ltd. (Japan) ', 'Maruho Co., Ltd. (Japan) ', 'miraDry, Inc. (US) ', 'SweatBlock (US) ', 'Roivant Sciences Ltd. (Switzerland) ', 'Theravida, Inc. (US) ', 'Dr. August Wolff GmbH (Germany) ', 'Dr. Reddy's Laboratories Ltd. (India) ', 'GSK Plc (UK) ', 'Revance (US) ', 'NovaMedica (Russia)'

Healthcare providers are researching radiofrequency microneedling-based hyperhidrosis treatments and the outcomes seen in hyperhidrosis patients. Stakeholders are attempting to determine whether fractional microneedle radiofrequency treatment has long-term benefits, particularly for patients with primary axillary hyperhidrosis. These studies were evaluated using the hyperhidrosis disease severity scale (HDSS), which revealed that patients improved dramatically after treatment.

According to an article published in the International Hyperhidrosis Society in October 2020, excessive sweating of the armpits, hands, feet, head and face (craniofacial) and other relatively small body areas (such as under the breasts) can be treated with onabotulinumtoxinA. When used to treat excessive sweating under the arms, Botox has been shown to reduce sweating by 82-87%. The effects usually appear two to four days after treatment, with the full effects appearing within two weeks. Dryness typically lasts 4 to 12 months, but some studies have found that it can last up to 14 months.

North America is anticipated to dominate the global hyperhidrosis treatment market. Due to the high prevalence of various illnesses and existence of major market participants in the nation, the United States retains a sizable portion of the market. About 3% of Americans suffer from hyperhidrosis, which most frequently affects people between the ages of 20 and 60. Additionally, the growth of this market in the United States is anticipated to be fueled by rising research and development activities for hyperhidrosis treatment products in the country. This will result in higher acceptance of these products.